Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 4/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12841852 | 0.88 | CHKA (0.41) | KDRPARP1NSD2HDAC1 | |
| SCHEMBL12841776 | 0.88 | CHKA (0.44) | KDRPARP1NSD2HDAC1 | |
| SCHEMBL12842022 | 0.86 | HDAC1 (0.46) | PARP1SRCHDAC1 | |
| SCHEMBL12841655 | 0.82 | HDAC1 (0.48) | PARP1HDAC1 | |
| SCHEMBL12842020 | 0.82 | ALDH1A1 (0.42) | PARP1SRCHDAC1 | |
| SCHEMBL12841664 | 0.81 | KDM4E (0.43) | PARP1HDAC1 | |
| SCHEMBL12841858 | 0.81 | PARP1 (0.40) | PARP1HDAC1 | |
| SCHEMBL12772354 | 0.81 | KDR (0.43) | KDRPARP1NSD2CHRM3SIGMAR1 | |
| SCHEMBL12841893 | 0.80 | MEN1 (0.51) | KDRPARP1HDAC1 | |
| SCHEMBL12842053 | 0.80 | KDM4E (0.41) | KDRPARP1SRCHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | disclosed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | KDR 3252/4885PARP1 161/4885NSD2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.